| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Eli Lilly and Company (NYSE:LLY) stock is trading lower on Thursday after Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the advancement of its novel treatment for obesity, VK2735.
The Details: Viking is advancing the injectable form of VK2735 to Phase 3 after receiving written feedback from an FDA Type C meeting. Also, the Phase 2 venture study of the drug yielded promising results.
VK2735 demonstrated an approximately 15% reduction in body weight from baseline following 13 weeks of treatment. The company anticipates scheduling an end-of-Phase 2 meeting with the FDA later this year.
In addition, the Phase 1 study for the oral formulation of VK2735 demonstrated positive results. Participants reported a mean weight loss of up to 5.3% from baseline following 28 days of daily oral dosing. The company expects to start a Phase 2 study of this formulation during the fourth quarter of 2024.
Both forms of the new pharmaceutical appeared to be safe and well tolerated.
Related Link: Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
LLY Price Action: As of Thursday morning, Eli Lilly shares are trading 4.19% lower at $823.87 per data from Benzinga Pro.
Image: Photo by rafapress on Shutterstock
